AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026

Reuters

2025/09/30

AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026

**AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating "Royalty Management Co," which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and "Biopharma Co," which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536985-en) on September 29, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2571508413"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571508413\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571508413?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571508413","market":"us","top_or_hot":-1,"title":"AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating \"<a href=\"https://laohu8.com/S/RMCO\">Royalty Management</a> Co,\" which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and \"Biopharma Co,\" which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536985-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating \"<a href=\"https://laohu8.com/S/RMCO\">Royalty Management</a> Co,\" which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and \"Biopharma Co,\" which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536985-en) on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL9wn2Lc:1","article_id":"2571508413","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571508413","pubTimestamp":1759176358,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. , a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating \"Royalty Management Co,\" which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and \"Biopharma Co,\" which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","ANAB":"Anaptysbio Inc","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"AnaptysBio将在2026年底前拆分为两家上市公司，分离生物制药业务和特许权使用费资产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":0.9,"NDAQ":0.9},"content_text":"AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026\n    \n\n        **AnaptysBio Announces Plans to Split into Two Public Companies** SAN DIEGO, Sept. 29, 2025 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, announced today that its Board of Directors has approved plans to separate its business into two independent, publicly traded companies by the end of 2026. The move is designed to unlock value by creating \"Royalty Management Co,\" which will manage royalty and milestone payments from collaborations such as Jemperli with GSK and imsidolimab with Vanda, and \"Biopharma Co,\" which will focus on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. The company will discuss details of the planned separation during a conference call and webcast with investors today at 4:30pm ET.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536985-en) on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}